Alzheimers - Articles | CARLAT PUBLISHING

Fact Sheet

Dementia with Lewy Bodies: Treatment

August 2, 2025

Dr. Aziz has no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Dementia with Lewy Bodies (DLB) is a progressive neurodegenerative disorder characterized by the presence of Lewy bodies in the brain.

Fact Sheet

Dementia with Lewy Bodies: Diagnosis

August 2, 2025

Rehan Aziz, MD

Dr. Aziz has no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Lewy Body Dementia (LBD) is a progressive neurodegenerative disorder.

Fact Sheet

Alzheimer’s Dementia: Stages and Treatment

August 2, 2025

Rehan Aziz, MD

Dr. Aziz has no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Alzheimer’s Dementia (AD) is a progressive neurodegenerative disorder that primarily impacts older adults.

Fact Sheet

Alzheimer’s Dementia: Diagnosis and Evaluation

August 2, 2025

Rehan Aziz, MD

Dr. Aziz has no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Alzheimer’s Dementia (AD) is the most common type of dementia, comprising about 60%–70% of all dementia cases and impacting 6.2 million Americans over age 65.

FDA Clears First Alzheimer's Blood Test—What's Actually New Here?

May 21, 2025

Daniel Carlat, MD

This week, the FDA cleared the first blood test for Alzheimer’s disease: the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio.It sounds like a big step forward. Maybe it will prove to be one. But after 22 years of Carlat Report coverage of overhyped tests and treatments, I’ve learned to pause before celebrating “firsts.”

Clinical Update

Lecanemab Breaks Thin Ground in Dementia

May 1, 2024

Chris Aiken, MD

Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report. Assistant Professor, NYU Langone Department of Psychiatry. Practicing psychiatrist, Winston-Salem, NC.

Dr. Aiken has no financial relationships with companies related to this material.

Concerns arise regarding lecanemab’s efficacy, high cost, and a notable risk of cerebral edema.

shutterstock_2417738561_PeopleImages.com_Yuri A.png

COMMENTARY

Insights About a Rare Transmissible Form of Alzheimer's Disease

February 9, 2024

Rehan Aziz, MD

Researchers found a connection between Alzheimer's disease and the use of contaminated growth hormone from human cadavers, highlighting the importance of understanding Alzheimer's pathology for better treatment development.

CLINICAL UPDATE

Low-Dose Lithium to Delay Dementia?

September 1, 2022

Jim Phelps, MD

James Phelps, MD. Psychiatrist Emeritus, Samaritan Mental Health, Corvallis, OR. Medical Director, PsychEducation.org. Dr. Phelps, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Current medications for dementia do little more than temporarily slow the cognitive decline, but new evidence suggests that tiny doses of lithium can significantly delay the onset.

Structural Brain Changes: How Imaging Affects Management of Late-Life Psychiatric Conditions

July 1, 2022

Oluwole Jegede, MD, PhD

Olusola Alade Ajilore, MD, PhD

Associate professor, Department of Psychiatry, University of Illinois College of Medicine, Chicago, IL.

Dr. Ajilore, expert for this educational activity, is an employee of KeyWise AI and an advisor for Embodied Labs, Blueprint, and Sage Therapeutics. All of the relevant financial relationships listed for this individual have been mitigated.

When does imaging change management? Dr. Ajilore describes when to order neuroimaging and what to look for. He walks us through various imaging modalities (both structural and functional) that can point us toward the correct diagnosis.

Q&A

Treating Agitation in Patients with Dementia

September 13, 2021

Eran Metzger, MD

Eran Metzger, MD

Medical Director of Psychiatry, Hebrew SeniorLife, Boston, MA. Assistant Professor of Psychiatry, Harvard Medical School, Boston, MA.

Dr. Metzger has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

The behavioral and psychological symptoms of dementia can be challenging to manage. Dr. Metzger discusses his approach in the diagnosis and treatment of agitated patients with dementia.